Adaptimmune Therapeutics (NASDAQ:ADAP) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of Adaptimmune Therapeutics (NASDAQ:ADAP) in a research report released on Sunday. The firm issued a buy rating on the biotechnology company’s stock.

A number of other brokerages also recently issued reports on ADAP. Scotiabank cut their price objective on Adaptimmune Therapeutics from $3.15 to $1.40 and set a “sector outperform” rating for the company in a research report on Friday, March 21st. Wells Fargo & Company dropped their price target on shares of Adaptimmune Therapeutics from $2.00 to $1.50 and set an “equal weight” rating for the company in a research report on Friday, March 21st. Guggenheim reduced their price target on shares of Adaptimmune Therapeutics from $3.00 to $1.75 and set a “buy” rating on the stock in a research note on Wednesday, March 26th. Finally, HC Wainwright lowered their price objective on shares of Adaptimmune Therapeutics from $3.50 to $3.00 and set a “buy” rating for the company in a research report on Tuesday, April 1st. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $1.83.

Adaptimmune Therapeutics Stock Performance

NASDAQ:ADAP opened at $0.26 on Friday. The company’s 50-day moving average is $0.47 and its two-hundred day moving average is $0.63. Adaptimmune Therapeutics has a 1-year low of $0.20 and a 1-year high of $1.48. The company has a debt-to-equity ratio of 0.62, a current ratio of 3.85 and a quick ratio of 3.82. The firm has a market capitalization of $66.39 million, a price-to-earnings ratio of -1.17 and a beta of 2.85.

Adaptimmune Therapeutics (NASDAQ:ADAP) last released its quarterly earnings data on Monday, March 24th. The biotechnology company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.09). The business had revenue of $3.22 million during the quarter, compared to analyst estimates of $16.56 million. Adaptimmune Therapeutics had a negative net margin of 25.43% and a negative return on equity of 74.15%. Analysts forecast that Adaptimmune Therapeutics will post -0.14 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in ADAP. Two Sigma Investments LP lifted its holdings in Adaptimmune Therapeutics by 33.5% during the 4th quarter. Two Sigma Investments LP now owns 76,347 shares of the biotechnology company’s stock worth $41,000 after buying an additional 19,146 shares in the last quarter. Virtu Financial LLC increased its position in shares of Adaptimmune Therapeutics by 21.5% during the fourth quarter. Virtu Financial LLC now owns 122,696 shares of the biotechnology company’s stock worth $66,000 after acquiring an additional 21,688 shares during the period. Invesco Ltd. raised its stake in shares of Adaptimmune Therapeutics by 82.0% in the fourth quarter. Invesco Ltd. now owns 63,335 shares of the biotechnology company’s stock valued at $34,000 after acquiring an additional 28,526 shares in the last quarter. FMR LLC boosted its holdings in Adaptimmune Therapeutics by 3.0% in the third quarter. FMR LLC now owns 1,740,900 shares of the biotechnology company’s stock valued at $1,655,000 after purchasing an additional 50,419 shares during the period. Finally, Rock Springs Capital Management LP grew its stake in Adaptimmune Therapeutics by 2.4% during the 4th quarter. Rock Springs Capital Management LP now owns 2,483,468 shares of the biotechnology company’s stock worth $1,338,000 after purchasing an additional 58,000 shares in the last quarter. Hedge funds and other institutional investors own 31.37% of the company’s stock.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.